gip glp 1 agonist tirzepatide The dual action of on various organs. GLP-1: Targeting GLP-1, GIP & GCG

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes

2025, p

Physiol Rep

Pharmaceutical giant Novo Nordisk recently conducted a large-scale study investigating whether weight-loss drug semaglutide could slow Alzheimers progression

With numerous criteria to consider, it can be confusing to determine which GLP-1 medication is ideal for each patient

The SURPASS trial (NCT04093752) will compare tirzepatide with liraglutide in high-risk patients with T2DM, while the SURMOUNT MMO study (NCT05556512) will evaluate the impact of tirzepatide on morbidity and mortality in patients with obesity